1,1-Dimethylethyl N-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]carbamate | 943845-57-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 1,1-Dimethylethyl N-[(2,3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)methyl]carbamate
• 英文别名: tert-butyl N-[(3-methyl-2-oxo-1,3-benzoxazol-5-yl)methyl]carbamate
• CAS: 943845-57-6
• 化学式: C₁₄H₁₈N₂O₄
• 分子量: 278.308
• InChiKey: ILXYKXMUAGMZBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Heterobicyclic metalloprotease inhibitors
  申请人：Bluhm Harald

  公开号：US20080221092A1

  公开（公告）日：2008-09-11

  The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.

  本发明通常涉及含有酰胺的杂双环含有药物作用的化合物，特别地，涉及含有酰胺的杂双环金属蛋白酶抑制剂。更具体地，本发明提供了一类新型的杂双环MMP-3和/或MMP-13抑制剂化合物，相对于目前已知的MMP-13和MMP-3抑制剂，这些化合物表现出更高的效力和选择性。
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• HETEROBICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Steeneck Christoph

  公开号：US20120015920A1

  公开（公告）日：2012-01-19

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• US7795245B2
  申请人：——

  公开号：US7795245B2

  公开（公告）日：2010-09-14
• [EN] HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉASE À MATRICE HÉTÉROBICYCLIQUE
  申请人：ALANTOS PHARM HOLDING

  公开号：WO2008063669A1

  公开（公告）日：2008-05-29

  [EN] The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.
  [FR] La présente invention concerne de manière générale des agents pharmaceutiques contenant une matrice hétérobicyclique contenant un amide, et en particulier des composés inhibiteurs de métalloprotéase hétérobicycliques contenant un amide. Plus particulièrement, l'invention propose une nouvelle catégorie de composés inhibiteurs de MMP-3 et/ou MMP-13 hétérobicycliques, qui présentent une valeur et sélectivité accrues par rapport aux inhibiteurs de MMP-13 et MMP-3 actuellement connus.